GSK and Vir Terminate Influenza Alliance a Year After Ending Covid-19 R&D Pact

GSK and Vir Biotechnology have ended their influenza collaboration, a move that follows last year’s Phase 2 failure for one of the partnered programs. Vir is now free to continue its flu research on its own, but the company says it’s actively pursuing other partners.